Myriad Illuminates High Court's Approach To Section 101

Law360, New York (July 8, 2013, 12:21 PM EDT) -- On June 13, 2013, the U.S. Supreme Court handed down its long-awaited decision in Association for Molecular Pathology v. Myriad Genetics Inc., in which it found claims to isolated DNA not patent eligible under 35 U.S.C. § 101. The Myriad opinion is interesting not only in its own right, but also for how it illuminates the Supreme Court’s recent approach to cases involving Section 101, an issue with a long and complex history reflecting a variety of legal tests and approaches.

An examination of Myriad together...
To view the full article, register now.